Silica 12CH

Phase 1Small molecule

HHOHM Foundation

Silica 12CH is one of 3 small molecule programs targeting Silicosis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SilicosisActive, not recruiting

SilicosisPhase 1

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Silicosis

#DrugCompanyPhaseTrials

Nydrazid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

—2

Esbriet

LLegacy Health System

Phase 2

1 3

Silica 12CH

HHOHM Foundation

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Silicosis1 trial

Using Silica 12CH to Mitigate the Effects and Symptoms of Silicosis in Brazil

Unknown status·HHOHM Foundation·Phase 1·NCT06011785·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Silica 12CH. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Silica 12CH compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Silica 12CH. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — HOHM Foundation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: HHOHM Foundation

Silica 12CH

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Silicosis1 trial

References

Drug Info

Quick Facts

Related News